Immutep Doses First Patient In AIPAC-003 Phase II/III Trial For Metastatic Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
Immutep has dosed its first patient in the AIPAC-003 Phase II/III trial for metastatic breast cancer. The trial aims to evaluate the safety and efficacy of the company's lead product candidate, eftilagimod alpha.
May 25, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immutep has initiated the AIPAC-003 Phase II/III trial for metastatic breast cancer, dosing its first patient and evaluating its lead product candidate, eftilagimod alpha.
The initiation of the AIPAC-003 Phase II/III trial and dosing of the first patient is a significant milestone for Immutep. This progress indicates that the company is advancing its lead product candidate, eftilagimod alpha, which could potentially lead to positive results and increased investor interest in the short term. As a result, the stock price is likely to go up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100